Clinical

ASCO 2025 highlighted breakthroughs, including improved cancer survival in key trials, new AI guideline tools, and expanding GLP-1 cancer research.

At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.

Studies indicate that ultrasound-based AI models significantly outperform sonographers in diagnosing ovarian cancer.

Panelists discuss how evidence-based, patient-tailored guideline adherence enhances long-term schizophrenia outcomes.

Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, emphasizing equity and education.

Exploration of pivotal data leading to the approvals of elranatamab and linvoseltamab, their efficacy, durability of response, and key safety considerations.

Explore the complexities of IgA nephropathy, its treatment advancements, and the challenges in early diagnosis and management in nephrology.

Panelists discuss how addressing social and structural barriers is essential to achieving equitable outcomes in schizophrenia care.

A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) glycemic measure.

Updated iMMagine-1 data presented at ASH 2025 show that anito-cel delivers deep, durable responses in heavily pretreated multiple myeloma.

This study found that certain characteristics in linked electronic health record data across episodes of care can help identify patients with Alzheimer disease and related dementias at high risk of 30-day readmissions.

Andrew Yee, MD, introduces the discussion by reviewing treatment challenges, patient education, and decision-making in relapsed/refractory multiple myeloma.

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and strategies for optimal patient care.

Fuzuloparib extended progression-free survival, regardless of the addition of apatinib in patients with newly diagnosed advanced ovarian cancer.

This year's top inflammation article highlighted the first FDA-approved treatment for patients with bronchiectasis.

This year's top ovarian cancer article highlighted gaps in physician knowledge of genetic testing that may affect patient care.

Influenza and COVID-19 are seeing an uptick in incidence as the winter months approach, making protecting vulnerable populations a high priority.

A phase 2b trial found vixarelimab rapidly reduced itch and lesion burden in prurigo nodularis, with sustained benefit and a favorable safety profile.

Top pieces from 2025 spanned outbreaks, an FDA drug approval, and the impact of NIH grant terminations.

The shift toward dual-targeting bispecifics and the imminent arrival of highly efficacious triple combinations could shift the follicular lymphoma treatment space.

Panelists discuss how the economic toll of poor LDL-C control demands workplace and systemwide prevention strategies.

Optimally positioning CD19-directed therapies in the follicular lymphoma treatment sequence requires consideration of both efficacy and the risk of sacrificing future options.

Experts at SABCS highlighted the aggressive nature of breast cancer in young women, emphasizing tailored management and support strategies.

The FDA approved subcutaneous amivantamab with recombinant human hyaluronidase for EGFR-mutated NSCLC based on the phase 3 PALOMA-3 trial.